Background The androgen receptor inhibitor enzalutamide is approved for the treatment of
metastatic castration-resistant prostate cancer that has progressed on docetaxel. Our aim …

Background Enzalutamide is an androgen receptor inhibitor with a demonstrated overall
survival benefit in metastatic castration-resistant prostate cancer. A phase 2 study of …

PURPOSE Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated
significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We …

Background Enzalutamide, an androgen-receptor inhibitor, has been associated with
improved overall survival in men with castration-resistant prostate cancer. It is not known …

5001 Background: In locally-advanced prostate cancer, the antiandrogen bicalutamide (Bic)
is used to maintain quality of life relative to castration therapy (LHRHa), but efficacy as a …

Background Men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising
prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that …

Background Enzalutamide is an oral androgen-receptor inhibitor that has been shown to
improve survival in two placebo-controlled phase 3 trials, and is approved for patients with …

Purpose A phase 2 study of enzalutamide monotherapy in patients with hormone naïve
prostate cancer demonstrated high prostate specific antigen response rates at 25 weeks, 1 …

In randomized clinical trials, the androgen‐receptor inhibitor enzalutamide has
demonstrated efficacy and safety in metastatic castration‐resistant prostate cancer …

Purpose This post hoc analysis evaluated treatment effects, safety, and pharmacokinetics of
enzalutamide in Korean patients in the phase 3, double-blind, placebo-controlled PREVAIL …